Beyond conventional care:The therapeutic potential of hemoperfusion in severe COVID-19  

作　　者：John Vásquez-Torres Ramses Dávila-Collado Leyla Abdalah-Perez Oscar Jarquin-Duran JoséSantos Latino Jorge Luis Espinoza 

机构地区：[1]Kidney and Hemodialysis Unit,Baptist Hospital of Nicaragua,Managua 2300,Nicaragua [2]Emergency Medicine,Baptist Hospital of Nicaragua,Managua 2300,Nicaragua [3]Faculty of Health Sciences,Kanazawa University,Kanazawa 920942,Japan

出　　处：《World Journal of Critical Care Medicine》2024年第4期88-98,共11页世界重症医学杂志（英文）

摘　　要：BACKGROUND Hemoperfusion(HP)is an extracorporeal blood purification modality utilized to remove small-to medium-sized molecules,such as toxins and cytokines,that are difficult to remove by conventional hemodialysis.In clinical practice,HP has been successfully used as a salvage therapy for drug overdose and occasionally in patients with liver failure and sepsis.AIM To summarize the clinical outcomes of a series of patients with severe coronavirus disease 2019(COVID-19)who received HP.METHODS Here,we summarize the clinical outcomes of a series of 18 patients with severe COVID-19 who received HP in our institution during the COVID-19 pandemic.A review of the literature was also performed.RESULTS HP was well-tolerated,and after an average of three sessions,respiratory and cardiovascular parameters as well as blood inflammatory markers improved in most patients.Ten patients were discharged alive.Our literature search identified a total of 20 studies(873 patients)in which HP was used for COVID-19.Nine studies reported improvements in respiratory parameters,and 13 studies(438 patients in total)reported better survival rates in patients undergoing HP.CONCLUSION HP was well-tolerated in patients with severe COVID-19,and most studies reported improved clinical parameters,including better survival rates,when HP was used in patients with severe COVID-19.Further research,especially prospective studies,is needed to evaluate the utility of HP as an early and supportive therapy for critically ill patients due to infectious diseases,such as those with COVID-19 or severe sepsis.

关 键 词：HEMOPERFUSION Cytokine storm Severe COVID-19 BLOOD Therapy SURVIVAL 

分 类 号：R47[医药卫生—护理学] R563.1[医药卫生—临床医学]